免疫性血小板減少症治療薬の世界市場規模・現状・予測2021年-2027年

QYResearchが発行した調査報告書(QY21JNE3799)
◆英語タイトル:Global Immune Thrombocytopenia Drugs Market Size, Status and Forecast 2021-2027
◆商品コード:QY21JNE3799
◆発行会社(リサーチ会社):QYResearch
◆発行日:2021年6月(※2024年版があります。お問い合わせください。)
◆ページ数:99
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医薬品
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,900 ⇒換算¥577,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD5,850 ⇒換算¥865,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,800 ⇒換算¥1,154,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

本調査資料では、免疫性血小板減少症治療薬の世界市場(2016年~2027年)を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模(トロンボポエチン受容体作動薬 (TPO-RAs)、コルチコステロイド、静脈免疫グロブリン (IVIGs)、その他薬剤)、用途別市場規模(バイオテクノロジー&製薬会社、病院&診断センター、学術機関&研究機関)、主要地域別市場規模(北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等)、企業情報などをまとめております。
・市場概要
・免疫性血小板減少症治療薬の市場動向
・企業の競争状況、市場シェア
・免疫性血小板減少症治療薬の種類別市場規模(トロンボポエチン受容体作動薬 (TPO-RAs)、コルチコステロイド、静脈免疫グロブリン (IVIGs)、その他薬剤)
・免疫性血小板減少症治療薬の用途別市場規模(バイオテクノロジー&製薬会社、病院&診断センター、学術機関&研究機関)
・免疫性血小板減少症治療薬の北米市場規模2016-2027(アメリカ、カナダ)
・免疫性血小板減少症治療薬の欧州市場規模2016-2027(ドイツ、フランス、イギリス等)
・免疫性血小板減少症治療薬のアジア市場規模2016-2027(日本、中国、韓国、インド、東南アジア等)
・免疫性血小板減少症治療薬の中南米市場規模2016-2027(メキシコ、ブラジル)
・免疫性血小板減少症治療薬の中東・アフリカ市場規模2016-2027(トルコ、サウジアラビア等)
・主要企業情報(Amgen Inc.、CSL Ltd.、Horizon Therapeutics Plc、Merck & Co., Inc.、Novartis AG、Rigel Pharmaceuticals Inc.)
・結論
【レポートの概要】

Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.

Market Analysis and Insights: Global Immune Thrombocytopenia Drugs Market
The global Immune Thrombocytopenia Drugs market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Immune Thrombocytopenia Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Immune Thrombocytopenia Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Immune Thrombocytopenia Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Immune Thrombocytopenia Drugs market.

Global Immune Thrombocytopenia Drugs Scope and Market Size
Immune Thrombocytopenia Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immune Thrombocytopenia Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Thrombopoietin Receptor Agonists (TPO-RAs)
Corticosteroids
Intravenous Immunoglobins (IVIGs)
Other Drugs

Segment by Application
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Centers
Academic Institutes and Research Organizations

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Amgen Inc.
CSL Ltd.
Horizon Therapeutics Plc
Merck & Co., Inc.
Novartis AG
Rigel Pharmaceuticals Inc.

【レポートの目次】

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immune Thrombocytopenia Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Thrombopoietin Receptor Agonists (TPO-RAs)
1.2.3 Corticosteroids
1.2.4 Intravenous Immunoglobins (IVIGs)
1.2.5 Other Drugs
1.3 Market by Application
1.3.1 Global Immune Thrombocytopenia Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Biotechnology and Pharmaceutical Companies
1.3.3 Hospitals and Diagnostic Centers
1.3.4 Academic Institutes and Research Organizations
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Immune Thrombocytopenia Drugs Market Perspective (2016-2027)
2.2 Immune Thrombocytopenia Drugs Growth Trends by Regions
2.2.1 Immune Thrombocytopenia Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Immune Thrombocytopenia Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Immune Thrombocytopenia Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Immune Thrombocytopenia Drugs Industry Dynamic
2.3.1 Immune Thrombocytopenia Drugs Market Trends
2.3.2 Immune Thrombocytopenia Drugs Market Drivers
2.3.3 Immune Thrombocytopenia Drugs Market Challenges
2.3.4 Immune Thrombocytopenia Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Immune Thrombocytopenia Drugs Players by Revenue
3.1.1 Global Top Immune Thrombocytopenia Drugs Players by Revenue (2016-2021)
3.1.2 Global Immune Thrombocytopenia Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Immune Thrombocytopenia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Immune Thrombocytopenia Drugs Revenue
3.4 Global Immune Thrombocytopenia Drugs Market Concentration Ratio
3.4.1 Global Immune Thrombocytopenia Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immune Thrombocytopenia Drugs Revenue in 2020
3.5 Immune Thrombocytopenia Drugs Key Players Head office and Area Served
3.6 Key Players Immune Thrombocytopenia Drugs Product Solution and Service
3.7 Date of Enter into Immune Thrombocytopenia Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Immune Thrombocytopenia Drugs Breakdown Data by Type
4.1 Global Immune Thrombocytopenia Drugs Historic Market Size by Type (2016-2021)
4.2 Global Immune Thrombocytopenia Drugs Forecasted Market Size by Type (2022-2027)

5 Immune Thrombocytopenia Drugs Breakdown Data by Application
5.1 Global Immune Thrombocytopenia Drugs Historic Market Size by Application (2016-2021)
5.2 Global Immune Thrombocytopenia Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Immune Thrombocytopenia Drugs Market Size (2016-2027)
6.2 North America Immune Thrombocytopenia Drugs Market Size by Type
6.2.1 North America Immune Thrombocytopenia Drugs Market Size by Type (2016-2021)
6.2.2 North America Immune Thrombocytopenia Drugs Market Size by Type (2022-2027)
6.2.3 North America Immune Thrombocytopenia Drugs Market Size by Type (2016-2027)
6.3 North America Immune Thrombocytopenia Drugs Market Size by Application
6.3.1 North America Immune Thrombocytopenia Drugs Market Size by Application (2016-2021)
6.3.2 North America Immune Thrombocytopenia Drugs Market Size by Application (2022-2027)
6.3.3 North America Immune Thrombocytopenia Drugs Market Size by Application (2016-2027)
6.4 North America Immune Thrombocytopenia Drugs Market Size by Country
6.4.1 North America Immune Thrombocytopenia Drugs Market Size by Country (2016-2021)
6.4.2 North America Immune Thrombocytopenia Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Immune Thrombocytopenia Drugs Market Size (2016-2027)
7.2 Europe Immune Thrombocytopenia Drugs Market Size by Type
7.2.1 Europe Immune Thrombocytopenia Drugs Market Size by Type (2016-2021)
7.2.2 Europe Immune Thrombocytopenia Drugs Market Size by Type (2022-2027)
7.2.3 Europe Immune Thrombocytopenia Drugs Market Size by Type (2016-2027)
7.3 Europe Immune Thrombocytopenia Drugs Market Size by Application
7.3.1 Europe Immune Thrombocytopenia Drugs Market Size by Application (2016-2021)
7.3.2 Europe Immune Thrombocytopenia Drugs Market Size by Application (2022-2027)
7.3.3 Europe Immune Thrombocytopenia Drugs Market Size by Application (2016-2027)
7.4 Europe Immune Thrombocytopenia Drugs Market Size by Country
7.4.1 Europe Immune Thrombocytopenia Drugs Market Size by Country (2016-2021)
7.4.2 Europe Immune Thrombocytopenia Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Immune Thrombocytopenia Drugs Market Size (2016-2027)
8.2 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Type
8.2.1 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Application
8.3.1 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Region
8.4.1 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Immune Thrombocytopenia Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Immune Thrombocytopenia Drugs Market Size (2016-2027)
9.2 Latin America Immune Thrombocytopenia Drugs Market Size by Type
9.2.1 Latin America Immune Thrombocytopenia Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Immune Thrombocytopenia Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Immune Thrombocytopenia Drugs Market Size by Type (2016-2027)
9.3 Latin America Immune Thrombocytopenia Drugs Market Size by Application
9.3.1 Latin America Immune Thrombocytopenia Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Immune Thrombocytopenia Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Immune Thrombocytopenia Drugs Market Size by Application (2016-2027)
9.4 Latin America Immune Thrombocytopenia Drugs Market Size by Country
9.4.1 Latin America Immune Thrombocytopenia Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Immune Thrombocytopenia Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Immune Thrombocytopenia Drugs Market Size (2016-2027)
10.2 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type
10.2.1 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application
10.3.1 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country
10.4.1 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Immune Thrombocytopenia Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Amgen Inc.
11.1.1 Amgen Inc. Company Details
11.1.2 Amgen Inc. Business Overview
11.1.3 Amgen Inc. Immune Thrombocytopenia Drugs Introduction
11.1.4 Amgen Inc. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.1.5 Amgen Inc. Recent Development
11.2 CSL Ltd.
11.2.1 CSL Ltd. Company Details
11.2.2 CSL Ltd. Business Overview
11.2.3 CSL Ltd. Immune Thrombocytopenia Drugs Introduction
11.2.4 CSL Ltd. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.2.5 CSL Ltd. Recent Development
11.3 Horizon Therapeutics Plc
11.3.1 Horizon Therapeutics Plc Company Details
11.3.2 Horizon Therapeutics Plc Business Overview
11.3.3 Horizon Therapeutics Plc Immune Thrombocytopenia Drugs Introduction
11.3.4 Horizon Therapeutics Plc Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.3.5 Horizon Therapeutics Plc Recent Development
11.4 Merck & Co., Inc.
11.4.1 Merck & Co., Inc. Company Details
11.4.2 Merck & Co., Inc. Business Overview
11.4.3 Merck & Co., Inc. Immune Thrombocytopenia Drugs Introduction
11.4.4 Merck & Co., Inc. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.4.5 Merck & Co., Inc. Recent Development
11.5 Novartis AG
11.5.1 Novartis AG Company Details
11.5.2 Novartis AG Business Overview
11.5.3 Novartis AG Immune Thrombocytopenia Drugs Introduction
11.5.4 Novartis AG Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.5.5 Novartis AG Recent Development
11.6 Rigel Pharmaceuticals Inc.
11.6.1 Rigel Pharmaceuticals Inc. Company Details
11.6.2 Rigel Pharmaceuticals Inc. Business Overview
11.6.3 Rigel Pharmaceuticals Inc. Immune Thrombocytopenia Drugs Introduction
11.6.4 Rigel Pharmaceuticals Inc. Revenue in Immune Thrombocytopenia Drugs Business (2016-2021)
11.6.5 Rigel Pharmaceuticals Inc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

...

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ 免疫性血小板減少症治療薬の世界市場規模・現状・予測2021年-2027年(Global Immune Thrombocytopenia Drugs Market Size, Status and Forecast 2021-2027)]についてメールでお問い合わせはこちらでお願いします。